

Eris, MJ Biopharm foray into India's insulin market

03 December 2021 | News

MJ Biopharm will be responsible for the development, manufacturing and supply of these products to the JV



Eris Lifesciences has announced its entry into India through Eris MJ Biopharm, a special purpose joint venture between Eris and Mumbai-based MJ Biopharm.

The 70:30 Joint Venture (with Eris holding a 70 per cent stake) will primarily engage in marketing and distribution of Human and Analogue Insulin including Aspart, Glargine and Lispro and GLP-1 agonists (e.g., Liraglutide) and potentially other biopharma products in India. MJ Biopharm will be responsible for the development, manufacturing and supply of these products to the JV.

Amit Bakshi, CMD, Eris Lifesciences, said "Given our strong market position in OAD and blockbuster brands like Zomelis and Gluxit, we are well-positioned to ride the growth wave in DPP4-SGLT2 combinations. With the formation of this JV, we will add Human Insulin, Analogues and GLP-1 agonists to our portfolio, which along with our Circa range of Glucometers, CGM Devices and HbA1C monitors, makes us a full-service player in diabetes care."

Amol Shah, MD, MJ Biopharm, said "With proven capabilities in biopharmaceutical development and manufacturing as well as world-class facilities, MJ Biopharm has built strong credibility in the insulin space, with 14+ million vials and 4+ million cartridges of recombinant human insulin manufactured and supplied to 25+ countries since 2015. I am excited about this collaboration with Eris and we look forward to expanding the breadth and depth of the insulin market in India."